Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nadim Ahmed
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
- Beta
- -0.01
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 4.09
Financials
Revenue
$0.00-100.0%Net Income
$-49.39MEBITDA
$-52.60MFree Cash Flow
$-43.08MEPS (diluted)
$-0.76Shares Outstanding (diluted)
64.60M+7975.1%Operating Expenses
$52.60MCash & Debt
$289.57MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-219.88M | $-3.72 |
| 2024 | $0.00 | $-167.38M | $-3.11 |
| 2023 | $0.00 | $-153.16M | $-3.69 |
| 2022 | $0.00 | $111.21M | $2.46 |
| 2021 | $18.94M | $-65.57M | $-1.48 |
| 2020 | $0.00 | $-51.80M | $-1.19 |
| 2019 | $0.00 | $-20.04M | $-19.70 |
| 2018 | $0.00 | $-14.19M | $-17.74 |
Valuation
CGEMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
43-18.75%Social Signal Score
Mentions (15)
- Newsglobenewswire.com·12d ago·Neutral
…and investments of $313.8 million as of September 30, 2026; runway into 2029 CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the third quarter ended September 30, 2026.
View source ↗ - Newszacks.com·24d ago·Positive
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect? The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsglobenewswire.com·45d ago·Positive
…ional Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that the first patient has been dosed in its pivotal Phase 2 study of CLN-049, a novel, investigational FLT3 T cell engager, in patients wi…
View source ↗ - Newsglobenewswire.com·52d ago·Negative
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
…g Pullback For CLN-978's Potential In Autoimmune Diseases I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical updates. CGEM has scheduled updates for its autoimmune pipeline for December 2026. The combined CLN-978 results could help corroborate its earlier data. Additionally, if CLN-978 becomes viable for more patients with a manageable safety profile, the potential repeat dosing also seems promising for better efficacy.
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 Cullinan Therapeutics NASDAQ: CGEM outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter.
View source ↗ - Newsglobenewswire.com·59d ago·Positive
… (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today outlined fourth quarter 2026 milestones across its immunology and oncology pipeline.
View source ↗ - Newsglobenewswire.com·62d ago·Positive
…to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at t…
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·69d ago·Positive
…REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m.
View source ↗ - Newsgurufocus.com·70d ago·Neutral
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e
View source ↗ - Newsbusinesswire.com·70d ago·Neutral
…ng Cancer PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the Inte…
View source ↗ - Newsglobenewswire.com·73d ago·Neutral
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026
View source ↗ - Newsseekingalpha.com·88d ago·Neutral
…s, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestones provide a potential funding bridge for advancing CGEM's autoimmune and oncology platforms. CLN-049's accelerated regulatory path in AML and CLN-978's promising early autoimmune data position CGEM for multiple commercialization opportunities.
View source ↗ - Newsbenzinga.com·101d ago·Negative
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape Taiho Oncology Inc., Taiho Pharmaceutical Co. Ltd., and Cullinan Therapeutics Inc. (NASDAQ:CGEM) on Thursday shared data from their global REZILIENT3 Phase 3 trial of zipalertinib in certain lung cancer patients.
View source ↗
Earnings
Tue, Mar 9(in 4 months)
Consensus estimate $-0.69 per share
Typical surprise +7.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.74 vs $-0.84beat
- Thu, Aug 6$-0.81 vs $-0.80miss
- Thu, May 7$-0.75 vs $-0.84beat
- Tue, Mar 10$-0.77 vs $-0.80beat
- Thu, Nov 6$-0.77 vs $-0.95beat
- Thu, Aug 7$-1.07 vs $-0.83miss
Estimates and results for CGEM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CGEM officers and directors.
- Bought
- $13.3m
- Sold
- $3.1m
8 trades
39 trades
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
- Michaelson Jennifersold
53 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CGEM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
